Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts

Neha Mehta-Shah, Matthew A. Lunning, Alison J. Moskowitz, Adam M. Boruchov, Jia Ruan, Peggy Lynch, Paul A. Hamlin, John Leonard, Matthew J. Matasar, Patricia L. Myskowski, Evan Marzouk, Sumithra Nair, Tamir Sholklapper, Veena Minnal, Maria L. Palomba, James Vredenburgh, Anita Kumar, Ariela Noy, David J. Straus, Andrew D. ZelenetzHeiko Schoder, Jurgen Rademaker, Wendy Schaffer, Natasha Galasso, Nivetha Ganesan, Steven M. Horwitz

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts'. Together they form a unique fingerprint.

Medicine & Life Sciences